Oncology Central

Endogenous virus expression could help predict RCC responsiveness to immune checkpoint therapy

Recently at the 2018 ASCO-SIC Clinical immune-oncology symposium (CA, USA, 25-27 January) a panel discussed the science presented in a new study (Abstract 104) entitled ‘Expression of endogenous retroviruses and response to immune checkpoint therapy in renal cell cancer (RCC)’.

“Increasing mutational burden is generally associated with increasing responses” to immune checkpoint inhibition, explained the lead author on the study, Shridar Ganesan from the Rutgers Cancer Institute of New Jersey (RJ, USA).  “However, there are some exceptions”, these include malignancies such as Merkel cell carcinoma, as well as RCC.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.